Log in
Pharmacology · Drugs and Prescriptions

Epoetin alfa

Epoetin alfa

Epoetin alfa (Epoetin alfa) is a recombinant drug belonging to the pharmacological group of agents affecting the blood system. As an analogue of human erythropoietin, it acts as a potent erythropoiesis-stimulating agent and is used as replacement therapy in conditions accompanied by a drop in endogenous growth factor synthesis.

Pharmacological groupAgents affecting the blood system (erythropoiesis-stimulating agents)
Nature of the substanceRecombinant glycoprotein (produced by genetic engineering)
Endogenous synthesis90% — renal peritubular cells, 10% — liver cells
Dosage form1 ml vials (2,000, 4,000, and 10,000 IU)
Route of administrationSubcutaneously and intravenously (30–100 IU/kg)
How to write a prescription
Rp.: Sol. Epoetini alfa 2000 ME - 1 ml
D.t.d. N 6 in flac.
S. П/к или в/в из расчёта 30–100 МЕ/кг массы тела 3 раза в неделю

Alternative prescriptions: Epoetini alfa 2000 IU - 1 ml; Sol. Epoetini alfa 1 ml (2000 IU); Sol. Epoetini alfa 4000 IU - 1 ml

Dosage form
1 ml vials of a solution containing 2,000, 4,000, and 10,000 IU
Administration
Subcutaneously and intravenously 30–100 IU per 1 kg of body weight
Group
Agents affecting the blood system
4 min readFor medical studentsUpdated 09/24/2026
Material prepared by WhiteCoat Pro editorial team based on platform study guidesReviewed by medical editor: Aulov A. A., general practitioner · 09/24/2026

Physiological role and mechanism of action

Endogenous erythropoietin is chemically a glycoprotein. It is a crucial growth factor synthesized predominantly in the peritubular cells of the kidneys (accounting for 90% of production), with the remaining 10% produced by liver cells. The primary trigger that causes the body to sharply increase the synthesis of this substance is tissue hypoxia.

Epoetin alfa, being a recombinant analogue, fully replicates the mechanism of action of the endogenous hormone:

  • The drug binds to specific high-affinity receptors (EpoR) located on the surface of immature erythroid cells.
  • It triggers the stimulation of proliferation and differentiation of hematopoietic progenitor cells (specifically, erythroid progenitor cells).
  • As a result, erythrocyte maturation is accelerated, and the release of young forms — reticulocytes — from the bone marrow into the systemic circulation is forced.

Indications for use

Erythropoietin preparations are prescribed for anemias of various origins when the body's own hormone is insufficient or potent bone marrow stimulation is required. Key indications include:

  • Chronic renal failure (CRF). This is a crucial pathophysiological link: when renal tissue is destroyed, the synthesis of endogenous erythropoietin drops critically, making Epoetin alfa replacement therapy vital.
  • Anemias associated with bone marrow disorders and malignant tumors.
  • Anemic states accompanying chronic inflammation and acquired immunodeficiency syndrome (AIDS).
  • Anemia of prematurity.
  • Anemia of chronic disease.
Test your knowledge on the topicTasks from the «Pharmacology» course bank — instant answers and explanations.

Differential pharmacotherapy of anemias

For successful treatment, it is essential to clearly understand in which types of anemia Epoetin alfa is not used. The drug is not a universal remedy and is not used in deficiency states requiring specific substrates:

  • Hyperchromic (megaloblastic) anemias: characterized by an increased color index and erythrocyte hemoglobin saturation. They arise due to impaired DNA synthesis. The drugs of choice here are Cyanocobalamin (Vitamin B12) and Folic acid (Vitamin B9).
  • Hypochromic (iron-deficiency) anemias: treated with iron preparations such as iron sulfate (Ferrous sulfate).

Metabolic note: For full hemoglobin synthesis and adequate production of erythropoietin itself, the body also requires Riboflavin (Vitamin B2), which participates in hematopoiesis in the form of its active coenzymes (FMN and FAD).

Dosage form and dosing regimen

The drug is intended exclusively for parenteral administration. Dosage is always calculated individually based on the patient's body weight.

  • Dosage form: Available as a solution in 1 ml vials. Available dosages contain 2,000, 4,000, and 10,000 IU (international units) of activity.
  • Routes of administration: The solution is administered subcutaneously or intravenously.
  • Dosage: The standard range is 30 to 100 IU per 1 kg of the patient's body weight.

Briefly: answers to topical questions

What side effects are characteristic of epoetin alfa?

During epoetin alfa therapy, elevated blood pressure, venous thromboembolic complications, and pure red cell aplasia are possible.

  • Arterial hypertension — erythropoietin is among the drugs that lead to an increase in blood pressure.
  • Venous thromboembolic complications — erythropoiesis-stimulating agents increase the likelihood of their development.
  • Pure red cell aplasia — there is a possibility of developing PRCA when prescribing epoetin alfa.

What laboratory blood parameters must be monitored during epoetin alfa therapy?

During epoetin alfa therapy, blood hemoglobin and reticulocyte levels must be monitored.

  • Hemoglobin — used to adjust the drug dose and determine the need to suspend treatment if levels rise above 130 g/l; the absence of an increase in Hb levels after prescribing ESAs at a standard dose for 1 month corresponds to the resistance criterion. A sudden decrease in hemoglobin concentration by 5–10 g/l per week combined with an absolute reticulocyte count of less than 10,000/µl is a criterion for suspecting PRCA.
  • Reticulocytes — an absolute reticulocyte count of less than 10,000/µl combined with a sharp decrease in hemoglobin or an increased need for blood transfusions is a criterion for suspecting PRCA.
How to memorize

EPOetin — EPOch of the Kidneys: 90% of Erythropoietin is Produced by the Kidneys. No kidneys (CKD) — no epoch (anemia), recombinant Epoetin alfa is needed.

Class and exam questions

Why does severe anemia develop in chronic kidney disease (CKD)?

The main source of endogenous erythropoietin is renal peritubular cells (90%). In CKD, this tissue dies, hormone synthesis drops, and the bone marrow ceases to produce erythrocytes in the required volume without replacement therapy.

What is the main trigger for erythropoietin production under normal conditions?

A sharp increase in the synthesis of this glycoprotein occurs in response to tissue hypoxia (oxygen starvation).

Will Epoetin alfa help in B12-deficiency anemia?

No. This is a hyperchromic megaloblastic anemia characterized by impaired DNA synthesis. The drug of choice here would be Cyanocobalamin, not erythropoiesis-stimulating agents.

Something unclear? Ask the AIThe AI tutor has read the material on "Epoetin alfa" and will explain it in simple terms.

What else to study on this topic

  • Comparison of the pharmacokinetics of Epoetin alfa and Epoetin beta preparations.
  • The role of vitamin B2 (Riboflavin) and its coenzymes in the production of endogenous erythropoietin.
  • Colony-stimulating factors (G-CSF and GM-CSF): mechanisms of action of filgrastim, sargramostim, and lenograstim.
  • Iron preparations (iron sulfate) in the treatment of hypochromic anemias.
  • EpoR receptors: molecular structure and intracellular signaling pathways.

Master the entire topic in the «Pharmacology» course

This is a summary. The course covers everything tested in classes and exams.

  • Complete study guide on "Epoetin alfa" and 5,304 more pages of the subject
  • Assignments and quizzes after every topic — just like in a colloquium
  • AI tutor answers questions on the topic anytime
  • 116 video lessons on the subject

Other topics in the «Drugs and Prescriptions» section

The entire "Drugs and Prescription" section

Free video lessons: pharmacologyShort lessons with study notes — no registration required.

Watch lessons

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.